Abstract
Health care reform has generated interest in identifying strategies to decrease health care costs without depriving patients of the health benefits of evidence-based therapies and generic formulations of drugs.1-3 The Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial recently showed that fenofibrate plus statins in patients with type 2 diabetes did not reduce cardiovascular events more than use of statins alone.4 The only other fenofibrate study, Fenofibrate Intervention and Event Lowering in Diabetes (FIELD), also failed to show reduced cardiovascular morbidity and mortality.5 These negative studies raise questions about a medication with more than $1 billion in sales in the United States.6

This publication has 21 references indexed in Scilit: